NLNK News and Press, NewLink Genetics From 10/30/19

AMES, Iowa, Oct. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an updat...

AMES, Iowa, Oct. 21, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing...

Minerva Neurosciences (NASDAQ: NERV )  -25%  following delay in schizophrenia drug results. More news on: Minerva Neurosciences, Inc., Pacific Coast Oil Trust, TD Ameritrade Holding Corporation, Stocks on the move, Read more ...

NewLink (NASDAQ: NLNK ) and Lumos Pharma sign a definitive merger agreement that will result in Lumos becoming a wholly-owned subsidiary and NewLink taking on the Lumos name and new "LUMO" ticker. More news on: NewLink Genetics Corporation, Tech stocks news, Healthcare stocks n...

-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma -- -- Lumos asset, LUM-201, represents first oral therapeutic candidate for pediatric growth hormone deficiency (PGHD) with planned Phase 2b expected...

SPI Energy (NASDAQ: SPI ) +60%  on the launch of its newly established hemp and CBD business. More news on: SPI Energy Co., Ltd., DAVIDsTEA Inc., Sintx Technologies, Inc., Stocks on the move, Read more ...

NewLink Genetics (NASDAQ: NLNK ) +14.6% after-hours on news that the U.S. Food and Drug Administration accepted the Biologics License Application and granted priority review for partner Merck's V920 investigational ebola vaccine. More news on: NewLink Genetics Corporation, Healthcare s...

AMES, Iowa, Sept. 17, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine ...

NewLink Genetics (NASDAQ: NLNK ): Q2 GAAP EPS of -$0.27 beats by $0.02 . More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

AMES, Iowa, July 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate develo...